Ipca stops US shipments of products from Ratlam facility

July 24, 2014 04:56 pm | Updated July 25, 2014 01:33 am IST - MUMBAI

Ipca Laboratories has voluntarily stopped shipments of active pharmaceutical ingredients (API) made at its Ratlam facility to the U.S.

This follows a recent inspection of the facility by the U.S. Food and Drug Administration, after which the company received certain inspection observations in Form 483 from the U.S. FDA. “Consequent to this, the company has voluntarily decided to temporarily suspend API shipments from this manufacturing facility for the U.S. markets till this issue is addressed,” a release said.

The voluntary stoppage would have an impact on its formulations export business to the U.S. since its formulations manufacturing units situated at Piparia (Silvassa) and SEZ, Indore (Pithampur), used the APIs manufactured from the Ratlam facility, the release added.

According to analysts, Form 483 does not imply a withdrawal from the market. However, since the company has voluntarily withdrawn the products, there could be an impact on a part of its API and formulation business in the U.S.

In 2013-14, the U.S. contributed sales of Rs.419.6 crore (12 per cent of total sales and 20 per cent of exports) of which, formulation: API mix is 61:39. According to Sarabjit Kour Nangra, Vice-President, Research, Angel Broking, the company has another API facility in Baroda which is U.S. FDA-approved.

“Thus, net impact on the company will depend on the time company takes to come out of the same (it will have to respond to the observation in 15 days, with a recourse and time line on resolving the issues) or shift its business to other U.S. FDA-approved facility,’’ she said.

On the Bombay Stock Exchange, the stock reacted significantly to touch a day’s low of Rs.711.45 before recovering to close at Rs.727.65, a loss of 13.06 per cent.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.